undamentalytics Newsletter
Sign in

Electromed, Inc. (ELMD) stock

Add to watchlist

Add holding +

NYSE: ELMD NYSE Health Care Equipment Next results ~November 10, 2026

B Fundamentals grade

Electromed, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in June.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$35

Cash-flow model

Base case. Range ~$27–$45 across our lower- and higher-growth cases (10.3%–20.3% a year).

Price vs value

Undervalued

The price is below our entire value range; our base value is 30% above it.

Price used: $26.76, November 2, 2026

Electromed, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 3 selling0 purchases and 9 sales by directors and officers, last 12 monthsInsider trades
  • Funds74 adding, 39 cuttingOf 22 active managers that changed their stake, 9 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Electromed files

Where Electromed stands after its latest 10-K

Revenue for the twelve months to June 2026 was $74m, up 15.3% on a year earlier, slower than the 16.8% growth a quarter earlier. Free-cash-flow margin fell to 11.3% from 17.3% a year earlier. Operating margin widened to 18.8% from 15.1%. The diluted share count is down 2.5% on a year earlier, which lifts each remaining share. Against its peers on growth, profitability, cash generation and balance sheet, it grades B. It passes 2 of our 2 financial-health checks. Our cash-flow model value is $34.18 a share, against a share price of $27.92. At that price, our model says the market is pricing in about 11.4% a year of cash-flow growth for five years, slower than the 15.6% a year revenue growth it has delivered.

Source: 10-K filed August 25, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 10, 2026 (estimated)

Electromed, Inc.'s trailing-twelve-month revenue grew 15.3% year on year, with a free-cash-flow margin of 11.3%. Where it stands out: operating margin of 18.8% ranks 14 of 132 health care equipment companies we cover. Where it lags: days sales outstanding of 147 days ranks 115 of 118 health care equipment companies we cover.

Our discounted-cash-flow model values the business at ~$35 per share in the base case (~$27–$45 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 24.6% while net income grew 49.9%: a 74pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Priced below our value. The share price of $26.76 is 30% below our value per share of $35.
  • Fast growth. Revenue grew 15.3% over the last 12 months, against a median of 9.1% for health care equipment companies we cover.
  • Margins widening. Operating margin is up 3.7 points on a year ago.
  • Shrinking share count. Diluted shares fell 2.5% in a year, so each share owns more of the business.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Results due soon. Results are expected around 11 November; the share price can move sharply on the day.
  • Volatile shares. Over the past year the shares showed annualised volatility of 50% and a beta of 0.6 against the S&P 500.
  • Weak cash conversion. Free cash flow was 74% of net income over the last 12 months.
  • Below peers: days sales outstanding. Days sales outstanding of 147 days ranks 115 of 118 health care equipment companies we cover (median 57 days).

Latest results: FY2026 Q4

Filed August 25, 2026
Earnings per share
$0.39 against an average estimate of $0.32: beat by 23.2%
Revenue
$19m, up 11.6% on a year earlier
Share reaction
-21.1% in the first session after the results on August 25, 2026, against +0.3% for the S&P 500
Next report
November 10, 2026

Electromed's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-1.0%
  • 1 week+0.5%
  • 1 month-4.8%
  • This year-8.1%
  • 1 year+11.2%
  • 5 years+140.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$73.8M
Operating margin
18.8%
Net margin
15.3%
EPS (TTM, diluted)
$1.30

Growth

Revenue growth
+15.3%
Change in growth rate
−1.5 pts
Share count change
−2.5%

Cash

Free cash flow (TTM)
$8.4M
FCF margin
11.3%
Stock pay % of revenue
3.7%

Earnings

Last results
August 25, 2026
Next results (est.)
November 11, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Electromed, Inc. valuation models and calculator

What the price is pricing in

The share price implies about 9.7% a year of cash-flow growth for five years.That is slower than the 15.6% a year revenue growth Electromed has delivered.

  • Priced in9.7%
  • Last 12 months15.3%
  • 3 years a year15.4%
  • 5 years a year15.6%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($26.76, Nov 2, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Hold12-month view
12-month price target
~$35
Price used
$26.76close November 2, 2026
Implied change
▲ +30%
Uncertainty
Medium

How we got here: a discounted-cash-flow model of Electromed, Inc.'s free cash flow after stock-based pay with after-tax interest added back ($7.9M, FY2026 Q4 TTM), growing 13.9% and 14.4% in the next two years (forecasts, guidance and its record), then back to 15.3% by year five, and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$27–~$45 ; that spread sets a 25% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of Electromed, Inc.'s free cash flow after stock-based pay ( $7.9M, FY2026 Q4 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value Electromed, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 8.6%: the 10-year Treasury yield (4.9%) plus a beta of 0.81 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$35 ~$27–$45 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. ~$25 ~$26–$46 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$13 ~$8.5–$20 Included
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$12 ~$11–$15 Included
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$24 ~$12–$35 4 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Electromed, Inc. with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −23%
  • Revenue growth 5 points higher ▲ +29%
  • Free-cash-flow margin 1 point lower ▼ −8%
  • Last year's free-cash-flow margin change, if it persists ▼ −33%
  • Discount rate 1 point higher ▼ −15%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $16$21$27$36$47$61
8.5% $13$16$21$27$35$45
10% $11$14$17$22$28$36

Valuation multiples over time Market data may be delayed

At fiscal year end 20162017201820192020202120222023202420252026
Share price$3.86$5.53$5.42$5.45$15.39$11.29$9.64$10.71$15.03$21.99$42.30
Market value$32m$47m$47m$47m$136m$101m$85m$93m$133m$196m$368m
+ Net debt (− = net cash)$0$0$0$0−$10m−$12m−$8m−$7m−$16m−$15m−$20m
Enterprise value$32m$47m$47m$47m$125m$89m$76m$86m$117m$181m$347m
Multiples
Price / sales 1.4x1.8x1.7x1.5x4.2x2.8x2.0x1.9x2.4x3.1x5.0x
Price / earnings 14.4x21.0x25.5x23.8x32.6x42.6x36.7x29.4x25.9x26.0x32.5x
Price / free cash flow 19.5x81.7x24.4x37.4x40.5x36.1x——15.2x17.6x43.7x
EV / EBITDA 8.5x11.1x13.8x12.9x21.9x24.5x22.0x18.8x15.9x16.9x23.5x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

69 /100

Moderate moat

How hard Electromed's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 10 / 20

    Cash operating profit has been a median 8.3% of total assets over 10 years.

  • Pricing power 20 / 20

    Gross margin has been a median 76.6%, moving by 1.2 percentage points (standard deviation) across 10 years.

  • Durability 12 / 20

    Operating margin has been a median 10.8%; its worst year was 7.1%.

  • Cash conversion 12 / 20

    Free cash flow was positive in 8 of 10 years, at a median 7.0% of revenue.

  • Discipline 16 / 20

    The diluted share count fell 2.5% over five years; stock-based pay has been a median 2.9% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 10, 2026, after the close. Analysts expect revenue of $19m for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $1.46 +12% $83m +13%
Next $1.69 +16% $92m +11%

Next year's EPS estimate has moved −4.5% in 90 days, across 2 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −1.7% on 90 days ago. In the last 30 days, 1 analyst raised Electromed, Inc.'s forecast and 1 cut it.

Consensus EPS forecast Electromed, Inc., last 90 days
$1.40 $1.50 $1.60 $1.70 $1.80 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $1.48 Current fiscal year, 60 days ago: $1.48 Current fiscal year, 30 days ago: $1.48 Current fiscal year, 7 days ago: $1.48 Current fiscal year, Now: $1.46 $1.46 Next fiscal year, 90 days ago: $1.77 Next fiscal year, 60 days ago: $1.77 Next fiscal year, 30 days ago: $1.77 Next fiscal year, 7 days ago: $1.77 Next fiscal year, Now: $1.69 $1.69

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $1.48$1.77
60 days ago $1.48$1.77
30 days ago $1.48$1.77
7 days ago $1.48$1.77
Now $1.46$1.69

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.32 $0.39 +23.2%
Dec 2025 $0.26 $0.32 +23.1%
Sept 2025 $0.20 $0.25 +21.9%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 25, 2026

No numeric guidance in Electromed, Inc.'s latest earnings release (filed August 25, 2026). Some companies give their outlook only on the earnings call.

How our valuation uses these forecasts

Our cash-flow model grows Electromed, Inc.'s revenue by +13.9% next year and +14.4% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+12.8%, weight 56%) and the company's own record (+15.3%, weight 44%) . How the weights are set.

Analyst recommendations

2 analysts, Oct 2026
Buy2100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202622

Counts of recommendations published by analysts covering Electromed, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
2.5%
of tradable shares
Days to cover
2.22
at average volume
Short interest, 1 month
−6%
to October 15, 2026
Held by institutions
62%
of shares
Held by insiders
17.2%
of shares
Employees
195
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +11.2%

$24.06 on October 31, 2025 to $26.76

ThenNowEffect
Revenue (last 12 months) $64m $74m +15.3%
Net margin 11.8% 15.3% +30.1%
P/E multiple 28.5x 20.6x −27.7%
Share count 9m 9m +2.6%

Biggest factor: p/e multiple.

Last 3 years +158.3%

$10.36 on November 3, 2023 to $26.76

ThenNowEffect
Revenue (last 12 months) $48m $74m +53.5%
Net margin 6.6% 15.3% +132.6%
P/E multiple 28.5x 20.6x −27.7%
Share count 9m 9m +0.1%

Biggest factor: net margin.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
ELMD+33%−19%+4%+171%−2%−8%
Industry peers (median)−9%−37%−9%−20%−16%−15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
ELMD75%50%58%75%42%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
ELMD−25%−34%−32%−24%−49%−44%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 56% from August 10, 2020 to November 3, 2020. Getting back needed a 127% gain, reached on May 3, 2024, 1277 days after the low.

Price behaviour

52-week range
$23.15 – $46.31
From 52-week high
−42.2%
vs 50-day average
−4.8%
vs 200-day average
−14.4%
Volatility (1 year)
50%
Beta vs S&P 500
0.63

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±12.9%
After a week
7 up, 5 down
typical move ±15.3%
After a month
6 up, 6 down
typical move ±22.7%
Results releasedNext dayS&P 500 next day5 days21 days
August 25, 2026 −21.1% +0.3% −32.7% −30.9%
May 12, 2026 +31.2% +0.4% +48.0% +45.0%
February 10, 2026 −8.5% −0.3% −10.1% −15.7%
November 12, 2025 +4.9% −1.6% +0.4% +18.9%
August 26, 2025 +22.6% +0.6% +18.0% +15.0%
May 13, 2025 −13.8% +0.8% −1.0% −10.8%
February 11, 2025 +11.1% −0.2% −2.0% −17.9%
November 12, 2024 +3.5% −0.3% +4.0% +6.6%
August 27, 2024 −0.1% −0.4% +11.7% +30.0%
May 7, 2024 −3.5% +0.1% −4.7% −16.8%
February 13, 2024 +28.1% −0.5% +50.1% +64.4%
November 7, 2023 −6.0% +0.4% +1.2% −0.8%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Options strategies

All options ideas

How Electromed, Inc.’s listed options are priced, and three ways to use them that follow from our valuation. Quotes are delayed, read November 2, 2026. Check the live chain at your broker before trading.

Cash-secured put

Not offered: fundamentals grade B (needs B+ or better).

We suggest selling a put only on well-rated companies, at a strike where the price you would pay if assigned (strike less premium) is at or below our fair value.

Covered call

Not offered: no liquid call at or above our price target — the model says the upside is worth more than any listed strike.

For holders: sell a call at a strike at or above our fair value, so the shares are only sold at a price the model calls full value.

Collar

Not offered: the shares trade below our fair value: a collar caps upside the model expects.

For holders of a stock trading at or above our fair value: buy a put for a floor and sell a call to pay for it.

General research, not personal advice. Options can lose you more than you expect and are not suitable for everyone: put sellers can be made to buy shares that keep falling, call sellers give up gains above the strike, and results or news can move prices sharply. Chances shown are approximations from each option’s delta. Spreads, fees and early assignment are not modelled.

Electromed, Inc. in five measures

Fundamentals grade B
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Electromed, Inc.
$40M $50M $60M $70M $80M FY24 Q1 FY24 Q4 FY25 Q3 FY26 Q4 Revenue (TTM), FY24 Q1: $49.7M Revenue (TTM), FY24 Q2: $51.7M Revenue (TTM), FY24 Q3: $53.5M Revenue (TTM), FY24 Q4: $54.7M Revenue (TTM), FY25 Q1: $57.1M Revenue (TTM), FY25 Q2: $59.6M Revenue (TTM), FY25 Q3: $61.4M Revenue (TTM), FY25 Q4: $64M Revenue (TTM), FY26 Q1: $66.2M Revenue (TTM), FY26 Q2: $68.9M Revenue (TTM), FY26 Q3: $71.8M Revenue (TTM), FY26 Q4: $73.8M $73.8M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY24 Q1 $49.7M
FY24 Q2 $51.7M
FY24 Q3 $53.5M
FY24 Q4 $54.7M
FY25 Q1 $57.1M
FY25 Q2 $59.6M
FY25 Q3 $61.4M
FY25 Q4 $64M
FY26 Q1 $66.2M
FY26 Q2 $68.9M
FY26 Q3 $71.8M
FY26 Q4 $73.8M
Revenue growth, TTM YoY Electromed, Inc.
12% 14% 16% 18% 20% FY24 Q1 FY24 Q4 FY25 Q3 FY26 Q4 Revenue growth, TTM YoY, FY24 Q1: 17.5% Revenue growth, TTM YoY, FY24 Q2: 18.0% Revenue growth, TTM YoY, FY24 Q3: 17.0% Revenue growth, TTM YoY, FY24 Q4: 13.8% Revenue growth, TTM YoY, FY25 Q1: 14.7% Revenue growth, TTM YoY, FY25 Q2: 15.3% Revenue growth, TTM YoY, FY25 Q3: 14.8% Revenue growth, TTM YoY, FY25 Q4: 17.0% Revenue growth, TTM YoY, FY26 Q1: 16.1% Revenue growth, TTM YoY, FY26 Q2: 15.5% Revenue growth, TTM YoY, FY26 Q3: 16.8% Revenue growth, TTM YoY, FY26 Q4: 15.3% 15.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY24 Q1 17.5%
FY24 Q2 18.0%
FY24 Q3 17.0%
FY24 Q4 13.8%
FY25 Q1 14.7%
FY25 Q2 15.3%
FY25 Q3 14.8%
FY25 Q4 17.0%
FY26 Q1 16.1%
FY26 Q2 15.5%
FY26 Q3 16.8%
FY26 Q4 15.3%
Operating margin (TTM) Electromed, Inc.
5% 10% 15% 20% FY24 Q1 FY24 Q4 FY25 Q3 FY26 Q4 Operating margin (TTM), FY24 Q1: 8.3% Operating margin (TTM), FY24 Q2: 9.9% Operating margin (TTM), FY24 Q3: 10.7% Operating margin (TTM), FY24 Q4: 12.0% Operating margin (TTM), FY25 Q1: 14.7% Operating margin (TTM), FY25 Q2: 14.5% Operating margin (TTM), FY25 Q3: 14.6% Operating margin (TTM), FY25 Q4: 15.1% Operating margin (TTM), FY26 Q1: 15.7% Operating margin (TTM), FY26 Q2: 16.7% Operating margin (TTM), FY26 Q3: 18.3% Operating margin (TTM), FY26 Q4: 18.8% 18.8%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY24 Q1 8.3%
FY24 Q2 9.9%
FY24 Q3 10.7%
FY24 Q4 12.0%
FY25 Q1 14.7%
FY25 Q2 14.5%
FY25 Q3 14.6%
FY25 Q4 15.1%
FY26 Q1 15.7%
FY26 Q2 16.7%
FY26 Q3 18.3%
FY26 Q4 18.8%
FCF margin (TTM) Electromed, Inc.
0% 5% 10% 15% 20% FY24 Q1 FY24 Q4 FY25 Q3 FY26 Q4 FCF margin (TTM), FY24 Q1: 2.4% FCF margin (TTM), FY24 Q2: 7.1% FCF margin (TTM), FY24 Q3: 8.9% FCF margin (TTM), FY24 Q4: 15.8% FCF margin (TTM), FY25 Q1: 19.8% FCF margin (TTM), FY25 Q2: 18.2% FCF margin (TTM), FY25 Q3: 19.3% FCF margin (TTM), FY25 Q4: 17.3% FCF margin (TTM), FY26 Q1: 13.2% FCF margin (TTM), FY26 Q2: 11.9% FCF margin (TTM), FY26 Q3: 13.0% FCF margin (TTM), FY26 Q4: 11.3% 11.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY24 Q1 2.4%
FY24 Q2 7.1%
FY24 Q3 8.9%
FY24 Q4 15.8%
FY25 Q1 19.8%
FY25 Q2 18.2%
FY25 Q3 19.3%
FY25 Q4 17.3%
FY26 Q1 13.2%
FY26 Q2 11.9%
FY26 Q3 13.0%
FY26 Q4 11.3%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2026, from the 10-K

Each dollar Electromed took in during FY2026, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.

  1. Revenue $73.8M
  2. Other income $479,000 · 0.6%
  3. Cost of revenue $15.8M · 21.5%
  4. Gross profit $57.9M · 78.5%
  5. Research and development $1.3M · 1.8%
  6. Selling, general and admin $42.7M · 57.9%
  7. Operating income $13.9M · 18.8%
  8. Income tax $3.1M · 4.1%
  9. Net income $11.3M · 15.3%

Shares of revenue. Source: Electromed's 10-K for FY2026, as filed with the SEC. Other income is income outside operations, such as investment gains.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2011 Jun 2011 2012 Jun 2012 2013 Jun 2013 2014 Jun 2014 2015 Jun 2015 2016 Jun 2016 2017 Jun 2017 2018 Jun 2018 2019 Jun 2019 2020 Jun 2020 2021 Jun 2021 2022 Jun 2022 2023 Jun 2023 2024 Jun 2024 2025 Jun 2025 2026 Jun 2026
Income
Revenue 19 20 15 15 19 23 26 28 31 32 36 42 48 55 64 74
Gross profit 14 14 10 11 14 18 21 22 24 25 27 31 37 42 50 58
EBITDA 2 1 −1 −0 2 4 4 3 4 6 4 3 5 7 11 15
Operating income 2 1 −2 −1 1 3 4 3 3 5 3 3 4 7 10 14
Net income 1 0 −1 −1 1 2 2 2 2 4 2 2 3 5 8 11
Diluted EPS $0.13 $0.02 −$0.16 −$0.16 $0.13 $0.27 $0.26 $0.21 $0.23 $0.47 $0.27 $0.26 $0.36 $0.58 $0.85 $1.30
Growth (year on year)
Revenue — +2.7% −22.6% +2.5% +25.3% +18.5% +12.5% +9.5% +10.6% +3.7% +10.1% +16.5% +15.4% +13.8% +17.0% +15.3%
EBITDA — −54.0% −234.7% — — +93.7% +12.9% −19.4% +7.2% +57.9% −37.0% −3.9% +31.2% +61.7% +45.2% +37.9%
Operating income — −67.6% −401.4% — — +137.3% +14.8% −24.0% +4.3% +80.9% −38.6% −5.4% +34.9% +64.2% +46.8% +43.7%
Net income — −82.3% — — — +102.5% +0.8% −17.9% +8.1% +110.1% −43.2% −2.4% +37.4% +62.7% +46.3% +49.9%
Diluted EPS — −84.6% — — — +107.7% −3.7% −19.2% +9.5% +104.3% −42.6% −3.7% +38.5% +61.1% +46.6% +52.9%
Margins
Gross margin 72.5% 72.4% 69.2% 68.7% 70.1% 77.7% 79.5% 76.9% 76.2% 77.6% 76.4% 75.5% 76.0% 76.3% 78.1% 78.5%
EBITDA margin 11.6% 5.2% −9.1% −1.1% 9.9% 16.2% 16.3% 12.0% 11.6% 17.7% 10.1% 8.3% 9.5% 13.5% 16.7% 20.0%
Operating margin 9.8% 3.1% −12.1% −4.8% 6.8% 13.5% 13.8% 9.6% 9.0% 15.8% 8.8% 7.1% 8.3% 12.0% 15.1% 18.8%
Net margin 5.6% 1.0% −8.8% −8.3% 5.6% 9.6% 8.6% 6.5% 6.3% 12.8% 6.6% 5.5% 6.6% 9.4% 11.8% 15.3%
Free-cash-flow margin −9.9% −10.1% 5.7% 7.6% 11.6% 7.1% 2.2% 6.8% 4.0% 10.3% 7.8% −5.1% −0.7% 16.0% 17.4% 11.4%
Cash flow
Cash from operations −1 −1 2 2 3 2 1 2 3 4 3 −1 1 9 11 10
Capital spending 0 1 1 1 1 1 1 1 1 1 0 1 2 0 0 1
Free cash flow −2 −2 1 1 2 2 1 2 1 3 3 −2 −0 9 11 8
Stock-based pay 0 0 0 0 0 0 0 1 1 1 1 1 1 2 3 3
Free cash flow after stock pay −2 −2 1 1 2 1 0 1 0 2 2 −3 −1 7 8 6
Balance sheet
Cash 4 2 1 2 4 — — — — 10 12 8 7 16 15 20
Total debt 4 3 1 1 1 1 1 — 0 0 0 0 0 0 0 0
Net debt (negative = net cash) −0 2 1 −0 −2 — — — — −10 −12 −8 −7 −16 −15 −20
Diluted shares 8m 8m 8m 8m 8m 8m 8m 9m 9m 9m 9m 9m 9m 9m 9m 9m
Returned to shareholders
Buybacks — — — — — — — — — — 1 1 0 0 10 4
Total returned — — — — — — — — — — 1 1 0 0 10 4

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $66m
Short-term assets $57mLonger-term assets $9m
What it owes, and who funded it · $66m
Short-term liabilities $12mLonger-term liabilities $0mShareholders' equity $54m
  • Short-term assets cover short-term liabilities $57m of assets due within a year against $12m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $57m short-term assets against $66,000 of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Electromed, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q4 TTM
Buybacks (TTM)
$3.9M
Returned to shareholders
47%
of free cash flow
Buybacks, last 3 fiscal years
$14.2M
Diluted share count
−2.5%
year over year
Total shareholder yield
1.8%
dividends 0.0% + buybacks 1.8% of market value
R&D spending
1.8%
of revenue
Sales & admin spending
57.9%
of revenue
Days sales outstanding
147 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated ELMD RCEL PDEX TELA SGHT LUNG Median
Revenue, last 12 months $74m $76m $80m $80m $83m $87m $99m
Revenue growth, last 12 months 15.3% 1.0% 13.3% 6.1% 9.3% −3.4% 9.2%
Revenue growth, 3-year average 15.4% 22.8% 19.2% 17.6% 0.8% 13.0% 13.5%
Revenue growth, latest quarter 11.6% 17.8% 11.0% −4.5% 19.5% −4.6% 10.2%
Gross margin 78.5% 81.6% 32.5% 67.8% 88.0% 77.1% 61.2%
Operating margin 18.8% −46.6% 16.8% −42.6% −33.4% −53.0% −8.5%
Operating margin, 3-year average 15.3% −69.8% 15.6% −50.7% −54.2% −64.4% −17.9%
Net margin 15.3% −57.0% 15.1% −51.5% −35.7% −55.0% −12.0%
Cash from operations / revenue 13.1% −32.0% 14.4% −39.0% −27.9% −34.9% −1.9%
Free-cash-flow margin 11.3% −32.5% 13.4% −39.6% −28.0% −35.1% −3.9%
Free-cash-flow margin, 3-year average 14.8% −65.3% 2.2% −51.2% −34.5% −39.2% −7.0%
Stock pay / revenue 3.7% 9.6% 0.8% 4.0% 12.9% 19.7% 6.1%
Change in share count −2.5% 14.7% −1.8% 14.4% 4.7% 4.7% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth 15.3% 9.1% 48 of 129
Change in growth rate Growth -1.5pp -0.6pp 83 of 129
Gross margin Profitability 78.5% 61.9% 19 of 123
Operating margin Profitability 18.8% -8.3% 14 of 132
Net margin Profitability 15.3% -12.0% 16 of 133
Free-cash-flow margin Cash generation 11.3% -3.4% 28 of 128
Stock pay as % of revenue Cash generation 3.7% 6.1% 48 of 123
Change in share count Balance sheet -2.5% 3.3% 13 of 115
Days sales outstanding Balance sheet 147 days 57 days 115 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$197M
Institutions reporting
128
Shares held vs prior quarter
▲ 2.5%
Positions opened / closed
33 / 7

Top buyers and sellers, Q2 2026: 74 institutions bought and 39 sold ; the biggest buyer was Invesco Ltd (+51K shares) and the biggest seller White Pine Capital LLC (−65K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
J.E. Simmons & Co., P.C. $20.5M 484K 10.4% ▼ 1.8%
Blackrock, Inc. $19.7M 466K 10.0% ▲ 1.5%
Vanguard Capital Management LLC $12M 283K 6.1% ▼ 15.5%
Acadian Asset Management LLC $9.4M 222K 4.8% ▼ 0.4%
Punch & Associates Investment Management, Inc. $9.2M 219K 4.7% ▼ 2.7%
Geode Capital Management, LLC $9.2M 217K 4.7% ▲ 7.5%
Dimensional Fund Advisors LP $7.6M 180K 3.9% ▲ 1.2%
Two Sigma Investments, LP $7.1M 167K 3.6% ▼ 17.7%
Hunter Associates Investment Management LLC $6.6M 156K 3.4% ▲ 3.4%
GAMCO Investors, Inc. Et Al $6M 142K 3.1% 0.0%
State Street Corp $4.8M 113K 2.4% ▲ 5.9%
Renaissance Technologies LLC $4.2M 100K 2.1% ▼ 19.6%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Electromed, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $2.2M 9 trades by 3 insiders · 0% under pre-set plans
Net ▼ $2.2M net selling
Insider Date Trade Shares Price Value
Cunniff James L. CEO and President June 8, 2026 Sell 1,026 $37.77 $38,752
Cunniff James L. CEO and President June 8, 2026 Sell 1,671 $36.80 $61,493
Cunniff James L. CEO and President June 8, 2026 Sell 7,003 $36.25 $253,859
Nagel Bradley M. Chief Financial Officer June 4, 2026 Sell 11,620 $36.34 $422,271
Nagel Bradley M. Chief Financial Officer June 4, 2026 Sell 181 $37.11 $6,717
Skarvan Kathleen Director May 15, 2026 Sell 9,256 $36.26 $335,623
Skarvan Kathleen Director May 15, 2026 Sell 19,032 $35.24 $670,688
Skarvan Kathleen Director May 15, 2026 Sell 3,562 $37.33 $132,969
Skarvan Kathleen Director May 15, 2026 Sell 8,150 $34.36 $280,034

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 11, 2026 estimated from the company's past filing pattern, not announced

  • August 25, 2026
  • May 12, 2026
  • February 10, 2026
  • November 12, 2025
  • August 26, 2025
  • May 13, 2025

Recent SEC filings

Data status

When each part of this page on Electromed, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Electromed, Inc. in brief

What does Electromed, Inc. do?
Electromed, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in June.
What is Electromed, Inc.'s stock ticker?
Electromed, Inc. trades under the ticker ELMD on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Electromed, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Electromed, Inc. reported revenue of $73.8M, 15.3% higher than a year earlier, according to its SEC filings.
What is Electromed, Inc.'s free cash flow?
Electromed, Inc.'s free-cash-flow margin is 11.3% of revenue over the trailing twelve months, ranking 28 of the 128 health care equipment companies we cover.
What is Electromed, Inc.'s fair value (intrinsic value) per share?
Our discounted-cash-flow model of Electromed, Inc.'s free cash flow after stock-based pay gives ~$35 per share in the base case, and ~$27–$45 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are Electromed, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are J.E. Simmons & Co., P.C., Blackrock, Inc. and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Electromed, Inc. buying back stock, and does it pay a dividend?
Electromed, Inc. spent $3.9M on share repurchases over the trailing twelve months, and its diluted share count fell 2.5% over the year.
What is Electromed, Inc.'s market cap?
On June 30, 2026, Electromed, Inc.'s market capitalisation was about $368M, with a price-to-earnings ratio of 32.5 and net debt of -$20.4M. Market figures come from third-party market data and may be delayed.
Who are Electromed, Inc.'s competitors?
In our Health Care Equipment peer group, the companies closest to Electromed, Inc. are Avita Medical, Inc., PRO DEX Inc, Tela Bio, Inc., Sight Sciences, Inc. and Pulmonx Corp. The side-by-side comparison below sets their revenue, margins and growth against Electromed, Inc.'s.
Are insiders buying or selling Electromed, Inc. stock?
Over the last 12 months, Electromed, Inc.'s directors and officers reported 0 open-market purchases and 9 sales on Form 4. The insider trading page charts every trade.
When is Electromed, Inc.'s next earnings date?
Around November 10, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Electromed, Inc. announces its own schedule.